Literature DB >> 18848893

Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.

L G Rodrigues1, M J Ferraz, D Rodrigues, M Pais-Vieira, D Lima, R O Brady, M M Sousa, M C Sá-Miranda.   

Abstract

Fabry disease (OMIM 301500) is a rare X-linked recessive disorder caused by mutations in the alpha-galactosidase gene (GLA). Loss of alpha-galactosidase (alpha-Gal) activity leads to the abnormal accumulation of glycosphingolipids in lysosomes predominantly of vascular endothelial cells. Clinically the disorder presents with angiokeratomas, clouding of the cornea, and renal, cardiac, and cerebrovascular complications. In addition, there is an increased incidence of neuropathic pain in Fabry patients. In this study, we investigated the implications of loss of alpha-galactosidase A activity on sensorimotor function and peripheral nervous system. Similar to the described in Fabry disease patients, the sensorimotor assessment of Fabry mice revealed diminished locomotor activity and warm hypoalgesia as assessed in the hot-plate. Moreover Fabry mice displayed alterations both in balance and co-ordination. By histological analysis, the cyto-architecture of Fabry mice sciatic nerves showed an increase in mean cross-sectional area accompanied by a decrease in the density of non-myelinated fibers as well as a trend for a decreased number of small myelinated fibers, a well established feature of Fabry disease. A relative preservation of large myelinated fibers and nerve conduction velocity measurements was observed. Our findings demonstrate for the first time that Fabry knockout mice have Gb3 accumulation in the peripheral nervous system, alterations in sensorimotor function, hypoalgesia and no impairment of motor nerve conduction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848893     DOI: 10.1016/j.nbd.2008.09.001

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  23 in total

Review 1.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

2.  Relative distribution of Gb3 isoforms/analogs in NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry.

Authors:  Philippe Provençal; Michel Boutin; Shaalee Dworski; Bryan Au; Jeffrey A Medin; Christiane Auray-Blais
Journal:  Bioanalysis       Date:  2016-08-15       Impact factor: 2.681

Review 3.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

4.  Neuropathic pain in a Fabry disease rat model.

Authors:  James J Miller; Kazuhiro Aoki; Francie Moehring; Carly A Murphy; Crystal L O'Hara; Michael Tiemeyer; Cheryl L Stucky; Nancy M Dahms
Journal:  JCI Insight       Date:  2018-03-22

5.  Kidney histologic alterations in α-Galactosidase-deficient mice.

Authors:  Carmen Valbuena; João Paulo Oliveira; Fátima Carneiro; Sandra Relvas; Mariana Ganhão; M Clara Sá-Miranda; Lorena G Rodrigues
Journal:  Virchows Arch       Date:  2011-02-16       Impact factor: 4.064

6.  Myelin Lipids Inhibit Axon Regeneration Following Spinal Cord Injury: a Novel Perspective for Therapy.

Authors:  Fernando M Mar; Tiago F da Silva; Marlene M Morgado; Lorena G Rodrigues; Daniel Rodrigues; Marta I L Pereira; Ana Marques; Vera F Sousa; João Coentro; Clara Sá-Miranda; Mónica M Sousa; Pedro Brites
Journal:  Mol Neurobiol       Date:  2015-01-13       Impact factor: 5.590

7.  Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model.

Authors:  Siamak Jabbarzadeh-Tabrizi; Michel Boutin; Taniqua S Day; Mouna Taroua; Raphael Schiffmann; Christiane Auray-Blais; Jin-Song Shen
Journal:  J Lipid Res       Date:  2020-08-31       Impact factor: 5.922

Review 8.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

9.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

Review 10.  Progress in the understanding and treatment of Fabry disease.

Authors:  James J Miller; Adam J Kanack; Nancy M Dahms
Journal:  Biochim Biophys Acta Gen Subj       Date:  2019-09-14       Impact factor: 3.770

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.